Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lessened by Baillie Gifford & Co.

Baillie Gifford & Co. lowered its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,260,724 shares of the company's stock after selling 420,303 shares during the period. Baillie Gifford & Co. owned 10.27% of Denali Therapeutics worth $306,035,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Denali Therapeutics in the 4th quarter worth $28,483,000. State Street Corp lifted its stake in shares of Denali Therapeutics by 26.4% in the 1st quarter. State Street Corp now owns 3,826,792 shares of the company's stock worth $123,108,000 after acquiring an additional 799,221 shares during the period. Millennium Management LLC acquired a new stake in shares of Denali Therapeutics in the 2nd quarter worth $18,992,000. BlackRock Inc. lifted its stake in shares of Denali Therapeutics by 6.7% in the 2nd quarter. BlackRock Inc. now owns 10,106,275 shares of the company's stock worth $298,236,000 after acquiring an additional 631,878 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Denali Therapeutics by 3.5% in the 3rd quarter. Vanguard Group Inc. now owns 10,597,781 shares of the company's stock worth $218,632,000 after acquiring an additional 354,798 shares during the period. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Stock Performance

NASDAQ:DNLI traded up $0.40 during mid-day trading on Tuesday, hitting $19.44. 884,361 shares of the company's stock traded hands, compared to its average volume of 1,160,110. The firm's 50 day simple moving average is $19.07 and its 200 day simple moving average is $19.40. Denali Therapeutics Inc. has a 1 year low of $15.45 and a 1 year high of $33.31. The company has a market cap of $2.71 billion, a PE ratio of -18.00 and a beta of 1.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.05). Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the previous year, the company earned ($0.75) EPS. On average, research analysts expect that Denali Therapeutics Inc. will post -2.62 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, insider Carole Ho sold 4,668 shares of Denali Therapeutics stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $19.02, for a total transaction of $88,785.36. Following the completion of the sale, the insider now directly owns 147,794 shares in the company, valued at $2,811,041.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Carole Ho sold 4,668 shares of Denali Therapeutics stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $19.02, for a total transaction of $88,785.36. Following the completion of the sale, the insider now directly owns 147,794 shares in the company, valued at $2,811,041.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Steve E. Krognes sold 92,500 shares of the firm's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the completion of the sale, the director now directly owns 47,341 shares in the company, valued at $970,490.50. The disclosure for this sale can be found here. Insiders sold a total of 115,623 shares of company stock worth $2,307,804 over the last ninety days. 7.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Citigroup began coverage on shares of Denali Therapeutics in a research note on Wednesday, December 13th. They issued a "buy" rating and a $32.00 target price for the company. HC Wainwright reduced their price objective on shares of Denali Therapeutics from $105.00 to $95.00 and set a "buy" rating for the company in a research note on Wednesday, February 28th. Wedbush reiterated an "outperform" rating and issued a $31.00 price objective on shares of Denali Therapeutics in a research note on Wednesday, February 28th. The Goldman Sachs Group reduced their price objective on shares of Denali Therapeutics from $73.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, February 29th. Finally, UBS Group reduced their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a "buy" rating for the company in a research note on Tuesday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $43.40.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.